Published in Medical Letter on the CDC and FDA, October 3rd, 2004
Products assigned for priority review by the FDA are those that appear to represent a potential therapeutic advance over existing therapies.
The company is seeking approval to manufacture and market cilansetron for the treatment of IBS-D in the United States.
"We are pleased...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.